TY - JOUR
T1 - Lipid lowering in liver and chronic kidney disease
AU - Herrick, Cynthia
AU - Litvin, Marina
AU - Goldberg, Anne Carol
N1 - Funding Information:
Dr. Herrick receives funding from National Institutes of Health Training Grant .
PY - 2014/6
Y1 - 2014/6
N2 - Lipid lowering, particularly with HMG CoA reductase inhibitors ("statins"), reduces the risk of cardiovascular disease. Patients with chronic liver and kidney disease present challenges to the use of lipid medications. In the case of most liver disorders, the concern has been one of safety. There is evidence that most lipid-lowering medications can be used safely in many situations, although large outcomes trials are not available. In contrast, in chronic kidney disease, dosing of lipid medications may require substantial modification depending on creatinine clearance. There are significant alterations in lipid metabolism in chronic kidney disease with concomitant increases in cardiovascular risk. Some data are available on cardiovascular outcomes with dyslipidemia treatment in renal patients. This review will examine lipid physiology and cardiovascular risk in specific liver and kidney diseases and review the evidence for lipid lowering and the use of statin and non-statin therapies in chronic liver and kidney disease.
AB - Lipid lowering, particularly with HMG CoA reductase inhibitors ("statins"), reduces the risk of cardiovascular disease. Patients with chronic liver and kidney disease present challenges to the use of lipid medications. In the case of most liver disorders, the concern has been one of safety. There is evidence that most lipid-lowering medications can be used safely in many situations, although large outcomes trials are not available. In contrast, in chronic kidney disease, dosing of lipid medications may require substantial modification depending on creatinine clearance. There are significant alterations in lipid metabolism in chronic kidney disease with concomitant increases in cardiovascular risk. Some data are available on cardiovascular outcomes with dyslipidemia treatment in renal patients. This review will examine lipid physiology and cardiovascular risk in specific liver and kidney diseases and review the evidence for lipid lowering and the use of statin and non-statin therapies in chronic liver and kidney disease.
KW - chronic kidney disease
KW - chronic liver disease
KW - dyslipidemia
KW - end stage renal disease
KW - ezetimibe
KW - fibrates
KW - statins
UR - http://www.scopus.com/inward/record.url?scp=84901352371&partnerID=8YFLogxK
U2 - 10.1016/j.beem.2013.11.006
DO - 10.1016/j.beem.2013.11.006
M3 - Review article
C2 - 24840263
AN - SCOPUS:84901352371
SN - 1521-690X
VL - 28
SP - 339
EP - 352
JO - Best Practice and Research: Clinical Endocrinology and Metabolism
JF - Best Practice and Research: Clinical Endocrinology and Metabolism
IS - 3
ER -